EPCAM

Across TCGA pan-cancer cohorts, EPCAM mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EPCAM data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EPCAM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPCAM expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where EPCAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.210	0.861	<.001	21	view →
PDAC	OS	Tertile	II,III,IV	0.722	0.387	.012	10	view →
LSCC	DFS	Tertile	II,III,IV	0.856	0.576	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EPCAM–LUAD (DFS)

Open the LUAD breakdown →